Sequence Bio is proud to announce that it has been named an Innovation Partner and Vendor of Record by Newfoundland and Labrador (NL) Health Services.
As an Innovation Partner and Vendor of Record, Sequence Bio will work with NL Health Services and other innovation partners to address challenges of high importance to both NL Health Services’ Innovation Strategy and the vision and action plans put forward by Health Accord NL.
“As a local company committed to putting Newfoundlanders and Labradorians first, we look forward to helping NL Health Services develop and implement innovative solutions that can deliver transformative benefits to the health and well-being of our province’s patients, health system, and economy while setting new precedents for other innovation ecosystems across the nation.” Said Lynn Healey, CEO of Sequence Bio.
Sequence Bio is one of 11 new Vendors of Record selected by NL Health Services from a large pool of local, national, and international organizations. Applications were rated using a multi-item form that included evaluations of the companies’ security architecture, and their technical, innovative, and software development capabilities.
“To be selected as an Innovation Partner and Vendor of Record alongside industry leaders like Amgen Canada and Amazon Web Services is a testament to our team’s expertise, hard work, and dedication,” said Healey.
For over a decade, Sequence Bio has worked to unlock the full potential of local health research to accelerate the development of better preventions, treatments, and medicines for diseases with high unmet clinical need.
“Open collaboration is critical for applying high-impact ideas to real-world healthcare problems,” said Healey. “We look forward to working with NL Health Services in realizing a shared vision of improved health outcomes and quality of care for all Newfoundlanders and Labradorians.”
Read the full announcement from NL Health Services here.
VP, Market Development